TapewireFind a company

person · Reporting owner

Hindson Benjamin J.

Disclosed activity across 1 company

Tapewire entity
19364
SEC CIK
0001786391

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
10x Genomics, Inc.TXG · Entity 2172Director · See RemarksAugust 24, 2026August 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

10x Genomics, Inc.

Report date August 24, 2026 · Filed August 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect488,182 Reported balance After 2026-08-24 transaction · row 1
1 source row

Row 1 · 2026-08-24 · Sale · Disposed 13,818 · Balance 488,182

F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 02, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,406 $139.13 $195,621.70
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $138.77 to $139.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,146 $138.06 $158,211.72
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,906

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $137.77 to $138.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,940 $136.98 $265,739.07
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,052

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $136.77 to $137.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 13,242 $136.11 $1,802,376.57
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,992

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $135.75 to $136.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,328 $135.36 $450,467.43
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,234

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $134.74 to $135.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 21,062 $0.88 $18,534.56
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:03 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 33,750 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-053573 · doc4.xml · derivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Class A Common Stock · 33,750 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:03 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 400 $126.88 $50,752.00
Disclosure

SEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:03 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 12,645 $125.98 $1,593,012.04
Disclosure

SEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,900

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $125.78 to $126.34. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:03 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 16,905 $125.47 $2,121,092.33
Disclosure

SEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,545

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $124.78 to $125.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:03 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,800 $124.26 $472,186.86
Disclosure

SEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,450

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $123.77 to $124.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:03 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 33,750 $0.88 $29,700.00
Disclosure

SEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 6,058 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · derivative · entry 13

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,250

Underlying: Class A Common Stock · 6,058 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F10 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 100 $114.90 $11,490.00
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 11

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 405 $114.10 $46,210.01
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 10

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,600

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F9 · price: This transaction was executed in multiple trades at prices ranging from $113.82 to $114.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 700 $112.93 $79,050.09
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 9

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,005

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F8 · price: This transaction was executed in multiple trades at prices ranging from $112.76 to $113.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,953 $112.07 $330,948.03
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 8

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,705

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $111.76 to $112.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,900 $111.40 $211,667.03
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 7

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,658

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $110.76 to $111.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 6,058 $0.88 $5,331.04
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 27,692 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · derivative · entry 12

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,308

Underlying: Class A Common Stock · 27,692 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F10 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,648 $115.34 $190,082.96
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $115.11 to $115.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 10,049 $114.55 $1,151,099.89
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,148

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $114.07 to $115.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 12,595 $113.67 $1,431,653.50
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,197

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $113.07 to $114.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,400 $112.73 $383,294.24
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,792

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $112.07 to $113.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 21:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 27,692 $0.88 $24,368.96
Disclosure

SEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,192

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:53 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 33,750 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-045149 · doc4.xml · derivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Class A Common Stock · 33,750 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 600 $101.24 $60,745.98
Disclosure

SEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $101.18 to $101.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,100 $100.52 $211,095.99
Disclosure

SEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,100

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $100.06 to $101.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 25,054 $99.33 $2,488,668.94
Disclosure

SEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,200

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $99.03 to $100.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 5,996 $98.76 $592,176.35
Disclosure

SEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,254

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $98.025 to $99.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:53 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 33,750 $0.88 $29,700.00
Disclosure

SEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
July 01, 2020 Filed Jul 3, 2020 00:22 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 33,750 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-040741 · doc4.xml · derivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,750

Underlying: Class A Common Stock · 33,750 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
July 01, 2020 Filed Jul 3, 2020 00:22 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,211 $88.67 $107,379.37
Disclosure

SEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $88.50 to $88.875. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
July 01, 2020 Filed Jul 3, 2020 00:22 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 18,065 $87.92 $1,588,354.29
Disclosure

SEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,711

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from 87.50 to $88.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
July 01, 2020 Filed Jul 3, 2020 00:22 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 14,474 $87.11 $1,260,873.56
Disclosure

SEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,776

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $86.50 to $87.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
July 01, 2020 Filed Jul 3, 2020 00:22 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 33,750 $0.88 $29,700.00
Disclosure

SEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 33,750 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · derivative · entry 8

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,500

Underlying: Class A Common Stock · 33,750 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F8 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 5,552 $81.86 $454,463.96
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 7

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $81.65 to $82.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,600 $81.30 $699,191.18
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,052

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $80.65 to $81.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,800 $79.99 $383,928.48
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,652

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $79.65 to $80.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,700 $79.15 $372,019.10
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,452

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $78.65 to $79.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 7,000 $78.07 $546,459.90
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,152

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $77.59 to $78.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,098 $77.12 $238,911.25
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,152

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $76.595 to $77.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:55 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 33,750 $0.88 $29,700.00
Disclosure

SEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
May 01, 2020 Filed May 5, 2020 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 33,750 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-027170 · doc4.xml · derivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,250

Underlying: Class A Common Stock · 33,750 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
May 01, 2020 Filed May 5, 2020 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,120 $79.20 $88,704.78
Disclosure

SEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $79.09 to $79.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,116 $78.59 $637,822.64
Disclosure

SEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,620

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $78.06 to $79.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 7,394 $77.53 $573,241.29
Disclosure

SEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,736

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $77.065 to $78.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 17,120 $76.62 $1,311,718.99
Disclosure

SEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,130

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $76.06 to $77.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 33,750 $0.88 $29,700.00
Disclosure

SEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.